Q-omics provides the consensus-scored EPB41L4A-DT profile across patient tissues and cancer cell-line models. EPB41L4A-DT expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EPB41L4A-DT is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, EPB41L4A-DT RNA expression shows 16,389 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where EPB41L4A-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPB41L4A-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPB41L4A-DT survival associations across molecular data types. EPB41L4A-DT RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPB41L4A-DT RNA expression–survival associations across cancer types. High EPB41L4A-DT expression shows favorable associations in KIRC, KIRP, HNSC, MESO, LUAD and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EPB41L4A-DT RNA expression.
This table summarizes EPB41L4A-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for EPB41L4A-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPB41L4A-DT shows lower tumor expression in HNSC, LUAD, COAD, LUSC and THCA and higher tumor expression in CHOL. The HNSC box plot shows higher EPB41L4A-DT RNA expression in normal versus tumor tissue (log2 FC = −0.856, t-test p < 0.001).
This table shows molecular features associated with EPB41L4A-DT in patient tissues and cancer cell lines. In patient samples, EPB41L4A-DT shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, EPB41L4A-DT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
